BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38423992)

  • 21. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
    Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
    Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation.
    Vanhove T; Annaert P; Knops N; de Loor H; de Hoon J; Kuypers DRJ
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):50-55. PubMed ID: 29989304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects.
    Zhang Z; Gao X; Zhang P; Li Y; Fu M; Lin H; Feng S; Shen K; Yu G; Li X
    Br J Clin Pharmacol; 2023 Aug; 89(8):2561-2568. PubMed ID: 37005376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.
    Krishna G; Ma L; Prasad P; Moton A; Martinho M; O'Mara E
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):1-10. PubMed ID: 22176629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor.
    Desch M; Wunderlich G; Goettel M; Goetz S; Liesenfeld KH; Chan TS; Rosenbrock H; Sennewald R; Link J; Keller S; Wind S
    Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):91-103. PubMed ID: 34716565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study.
    Poggesi I; Li LY; Jiao J; Hellemans P; Rasschaert F; de Zwart L; Snoeys J; De Meulder M; Mamidi RNVS; Ouellet D
    Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):101-111. PubMed ID: 31673875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
    Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
    Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An Adaptive Physiologically Based Pharmacokinetic-Driven Design to Investigate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Molibresib (GSK525762) in Healthy Female Volunteers.
    Riddell K; Patel A; Collins G; Zhou Y; Schramek D; Kremer BE; Ferron-Brady G
    J Clin Pharmacol; 2021 Jan; 61(1):125-137. PubMed ID: 32820548
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
    Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
    J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug Interactions for Low-Dose Inhaled Nemiralisib: A Case Study Integrating Modeling, In Vitro, and Clinical Investigations.
    Patel A; Wilson R; Harrell AW; Taskar KS; Taylor M; Tracey H; Riddell K; Georgiou A; Cahn AP; Marotti M; Hessel EM
    Drug Metab Dispos; 2020 Apr; 48(4):307-316. PubMed ID: 32009006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Open-Label Assessment of the Effects of Itraconazole and Rifampicin on Balovaptan Pharmacokinetics in Healthy Volunteers.
    Derks MGM; Wandel C; Young A; Bolt SK; Meyenberg C
    Adv Ther; 2020 Nov; 37(11):4720-4729. PubMed ID: 32935287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
    Berger B; Kaufmann P; Koch A; Dingemanse J
    J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
    Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
    Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
    Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
    J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
    Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
    Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
    J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.